General Practice engagement: STI, HIV and viralhepatitis care: an Evidence Check rapid review An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health—June 2023 Evidence Check General practice engagement: STI, HIV and viralhepatitis care An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. June 2023. This report -Smith, Lena Sanci, Jane Hocking. General Practice engagement: STI, HIV and viralhepatitis care: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2023. doi:10.57022/lnur4773 Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency
ViralHepatitis in Pregnancy Skip to main contentMenuClinical GuidanceClinical Practice GuidelineViral Hepatitis in PregnancyViral Hepatitis in PregnancyClinical Practice GuidelineCPGNumber 6September 2023Jump toSearch pageResourcesShareTwitterFacebookLinkedInEmailPrintBy reading this page you agree to ACOG's Terms and Conditions. Read termsPurpose:The purpose of this document is to describe the specific types of viralhepatitis, their implications during pregnancy, the risk of perinatal transmission, and issues related to both treatment and prevention of infection.Target Population:Pregnant or postpartum women and individuals who screen positive for viralhepatitis infection. The onset of these conditions may have predated the perinatal period or may have occurred for the first time
Guide to conducting programme reviews for HIV, viralhepatitis and sexually transmitted infections Guide to conducting programme reviews for HIV, viralhepatitis and sexually transmitted infectionsGuide to conducting programme reviews for HIV, viralhepatitis and sexually transmitted infectionsGuide to conducting programme reviews for HIV, viralhepatitis and sexually transmitted infectionsISBN to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).Suggested citation. Guide to conducting programme reviews for HIV, viralhepatitis and sexually transmitted infections. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0
ViralHepatitis Testing ViralHepatitis Testing - Province of British Columbia×Get your booster dose| Rapid antigen testing kits are free at pharmacies * Skip to main content * Skip to main navigation * Skip to side navigation * Accessibility StatementMenu * Careers & HR * Services * Forms * News * Contact us * * BC Procurement Resourcesdefault_collectiondefault_frontend Systems * Urological System * Chronic PainViral Hepatitis TestingEffective Date: May 26, 2021Recommendations and Topics * Scope * Key Recommendations * Etiology and Risk Factors * Diagnosis * Controversies in Care: Birth Cohort Hepatitis C Testing * ResourcesScopeThis guideline provides guidance for the use of laboratory tests to diagnose acute and chronic viralhepatitis in adults (≥ 19 years
What is the evidence on existing national policies and guidelines for delivering effective tuberculosis, HIV and viralhepatitis services for refugees and migrants among Member States of the WHO European Region? IIIWHO HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 74What is the evidence on existing national policies and guidelines for delivering effective tuberculosis, HIV and viralhepatitis services Joint Infectious Diseases (JID) programme aims to improve prevention and care for tuberculosis, HIV, viralhepatitis and other infectious diseases in the WHO European Region through ensuring equal access to safe and adequate health services, providing relevant epidemiological surveillance, including laboratory services and networks, and building technical capacity to reduce barriers and boost uptake
Knowledge and occupational practices of beauticians and barbers in the transmission of viralhepatitis: A mixed-methods study in Volta Region of Ghana. Hepatitis B and C viral (HBV and HCV) infections are endemic in Ghana. Also, the National Policy on ViralHepatitis stipulates that there is unreliable data, limited knowledge, and a deficiency in research on viralhepatitis, especially among performed using Stata version 17.0 at a 95% significance level in the quantitative stage. Most street beauticians and barbers reported poor knowledge levels about HBV and HCV (67.0%), although the awareness of this viralhepatitis was high (88.2%). While almost one-third of the participants observed safe occupational practices (31.5%), about 29.0%, 49.4%, and 55.3% of them also followed hand hygiene
Time series analysis and scaling law characteristics of viralhepatitis from 2004 to 2023 in Zhejiang Province, China. Hepatitis significantly increases the global disease burden and has become a major public health issue worldwide. China is a high-risk area for viralhepatitis, which is also a serious public health problem. The scaling relationship between various types of hepatitis and population size was explained by a scaling law. Fixed-effects and random-effects meta-analyses were used to calculate a combined index of β based on the single-scale index from 2004 to 2023. Furthermore, the X11 process was employed to identify the structural components of the time series of various types of hepatitis. In the past 20 years, the proportion of patients with viralhepatitis in Zhejiang
Seroprevalence and molecular characterization of viralhepatitis and HIV co-infection in the Central African Republic. The Central African Republic (CAR) is one of the countries with the highest prevalence of viralhepatitis infection in the world. Coinfection with HIV increases the morbidity and mortality beyond that of mono-infection with either hepatitis or HIV. The present study describes the geographic distribution of viralhepatitis infections and molecular characterization of these viruses in the CAR. Out of 12,599 persons enrolled during the fourth Multiple Indicator Cluster Survey of 2010 in the CAR, 10,621 Dried Blood Spot (DBS) samples were obtained and stored at -20°C. Of these DBS, 4,317 samples were randomly selected to represent all regions of the CAR. Serological tests for hepatitis
Trends in hepatocellular carcinoma and viralhepatitis treatment in older Americans. Incidence of hepatocellular carcinoma (HCC) had been increasing steadily among older Americans but plateaued in 2015-2017. Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) are important causes of HCC. The impact of improved treatments for these infections on recent trends in HCC incidence is unclear. To examine the relationship between use of antiviral therapy for chronic viral hepatis and HCC incidence in older Americans. We used 2007-2017 data from the Surveillance, Epidemiology, and End Results-Medicare database to estimate age-standardized incidence rates and average annual percent changes (AAPCs) for viralhepatitis-attributable HCC among individuals ≥66 years. We analyzed
Global progress, challenges and strategies in eliminating public threat of viralhepatitis. The problem caused by viralhepatitis is a major public health challenge faced in the past decade, and the global goal of eliminating viralhepatitis by 2030 is still far away. With the use of hepatitis B vaccine and the launch of new drugs, there are more means to control viralhepatitis and more technologies to prevent, diagnose and treat it. While improving the coverage of vaccine use, drugs for treating hepatitis B are not only becoming more effective, but also decreasing in price. The objective of this article was to explore the urgent issues that need to be addressed in global viralhepatitis with the increasing availability of vaccines and antiviral drugs. The updated World Health Organization
Putting people at the center: methods for patient journey mapping of viralhepatitis services across two LMICs in the Asia Pacific. To ensure that health services are high-quality, trusted and used by the population, their design and improvement should start from the perspective of what matters to people. Patient journey mapping (PJM) is one research method that centers the experiences of individuals living with health conditions and follows their pathways through care and recovery. This paper describes a novel, qualitative PJM methodology used in Vietnam and the Philippines to inform the co-design of a people-centered viralhepatitis screening, care and treatment pathway for individuals living with chronic hepatitis, which is a significant public health concern in the Asia-Pacific region
Overcome Health Inequities to Eliminate ViralHepatitis. This Viewpoint outlines the progress made toward eliminating hepatitis B and C but emphasizes the work that remains to prioritize diagnosis and treatment of populations disproportionately affected by viralhepatitis, including ensuring that there are systems in place to treat those infected and care for those at risk.
Prevention and management of viralhepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viralhepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western
People in community corrections are a population with unmet need for viralhepatitis care. To reach World Health Organization elimination targets for hepatitis C, different strategies are needed to reach people who have not yet been diagnosed and treated. In the context of declining treatment initiation rates, innovation in service design and delivery is necessary: testing and treatment needs
Chronic ViralHepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC. The impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the development of cirrhosis and hepatocellular carcinoma (HCC) by chronic hepatitis B (CHB) or C infection and antiviral treatment statuses is not well known. A total of 336,866 adults aged ≥30 years were prospectively and HCC, with HR of 1.23 (1.01-1.49) and 1.32 (1.05-1.65), respectively. These findings underscore the need to prioritize treatment of chronic viralhepatitis before addressing MASLD.
Progress towards elimination of viralhepatitis: a Lancet Gastroenterology & Hepatology Commission update. The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viralhepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viralhepatitis, we convene national experts from each of the top 20 highest burdened countries to provide an update on progress. Although the global burden of diseases is falling, progress towards elimination varies greatly by country. By use of a hepatitis elimination policy index conceived as part of the 2019 Commission, we measure countries
Association of Cognitive Impairment With Chronic ViralHepatitis Among Older Adults in Taiwan. To evaluate the risk of cognitive impairment among patients with chronic viralhepatitis. A cross-sectional study. Population-based. Individuals 60 years or older were enrolled from the Taiwan Biobank database from 2012. Hepatitis B virus and hepatitis C virus infections. Cognitive impairment was evaluated using the mini-mental state examination (MMSE). Logistic regression models were used to calculate odds ratios and 95% confidence intervals (CIs). The effects of APOE ε4 polymorphisms on the association between viralhepatitis and the risk of cognitive impairment were also investigated. We recruited 912 participants with cognitive impairment and 22 869 participants without cognitive impairment
Comparative analysis of perioperative and long-term outcomes of patients with hepatocellular carcinoma: Nonalcoholic fatty liver disease versus viralhepatitis. Despite the accumulating evidence regarding the oncological differences between nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) and viral infection-related HCC, the short- and long-term outcomes